The CRDMO Wilmington PharmaTech has announced a $50m expansion of its Delaware campus to more than double its current API reactor capacity.
In a statement, the company said that the investment was in response to growing demand for high-quality, US-based manufacturing.
The expansion will add two new 10,000-litre reactor suites, significantly increasing Wilmington's commercial‑scale manufacturing capabilities and enhancing its ability to support large‑scale production of small molecule APIs and peptides.
Wilmington added that the investment is part of the firm's second phase of its multi-year strategy to expand domestic API manufacturing capacity and builds on the company's recent addition of dedicated suites for the manufacture of highly potent API (HPAPI).
Together, the company says, these investments further position Wilmington as a preferred US‑based partner for biopharmaceutical innovators seeking a secure domestic supply.
"[During] the past decade, Wilmington has been among the few companies to actively invest in cGMP API manufacturing capacity in the US, including the recent addition of two new commercial-scale high-potency API suites," said Dr Hui-Yin "Harry" Li, founder and CEO of Wilmington PharmaTech.
This expansion builds on more than 20 years of cGMP manufacturing expertise and further strengthens our high-output scientific engine in solving complex chemistry challenges at scale.
"Curewell Capital is proud to support Wilmington in expanding high-quality commercial API production in the US," said Dr Kent Payne, Operating Partner at Curewell Capital and Managing Director at Wilmington PharmaTech.
We believe Wilmington is uniquely positioned to serve biopharmaceutical innovators with reliable, scalable domestic production, helping to bolster supply chain resilience and ensure patients have access to critical therapies.
Headquartered on a 54‑acre campus in Newark, Wilmington operates two adjacent, state‑of‑the‑art facilities with extensive cGMP manufacturing capabilities.